Innovative Birth Control Method: A Low-Dose, Once-Weekly Contraceptive Patch, Phase 3 Trials

Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women’s health products, announced today that after a successful end-of-Phase 2 meeting with the Food and Drug Administration (FDA), the company is moving forward with its pivotal Phase 3 program to support a NDA filing and marketing approval of AG200-15 with SKINFUSION? technology. AG200-15 is an innovative, low-dose contraceptive patch that offers women a convenient, once-weekly form of birth control.

More: continued here

Filed under: Sexual Health on November 21st, 2008